NASDAQ:BMRNBioMarin Pharmaceutical Stock Price, Forecast & News

BioMarin Pharmaceutical's stock was trading at $86.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BMRN shares have increased by 45.1% and is now trading at $126.06. View which stocks have been most impacted by Coronavirus.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioMarin Pharmaceutical.

BioMarin Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for BioMarin Pharmaceutical.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its quarterly earnings data on Wednesday, April, 29th. The biotechnology company reported $0.44 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.12 by $0.32. The biotechnology company earned $502.07 million during the quarter, compared to analyst estimates of $468.77 million. BioMarin Pharmaceutical had a return on equity of 3.62% and a net margin of 6.31%. BioMarin Pharmaceutical's revenue for the quarter was up 25.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.32) EPS. View BioMarin Pharmaceutical's earnings history.

BioMarin Pharmaceutical updated its FY 2020 After-Hours earnings guidance on Wednesday, April, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.85-1.95 billion, compared to the consensus revenue estimate of $1.97 billion.

21 brokerages have issued 1 year target prices for BioMarin Pharmaceutical's shares. Their forecasts range from $77.00 to $150.00. On average, they expect BioMarin Pharmaceutical's share price to reach $119.70 in the next year. This suggests that the stock has a possible downside of 5.0%. View analysts' price targets for BioMarin Pharmaceutical.

Media coverage about BMRN stock has trended negative recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioMarin Pharmaceutical earned a news impact score of -2.6 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about BioMarin Pharmaceutical.

Some companies that are related to BioMarin Pharmaceutical include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Celgene (CELG), Array Biopharma (ARRY) and Freeport-McMoRan (FCX).

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

BioMarin Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional investors include Manning & Napier Group LLC (0.54%), Envestnet Asset Management Inc. (0.08%), DNB Asset Management AS (0.06%), State of Alaska Department of Revenue (0.05%), Gradient Investments LLC (0.03%) and Arden Trust Co (0.00%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi, V Bryan Lawlis and Willard H Dere. View institutional ownership trends for BioMarin Pharmaceutical.

BMRN stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, and Arden Trust Co. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, V Bryan Lawlis, and Willard H Dere. View insider buying and selling activity for BioMarin Pharmaceutical.

BMRN stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, DNB Asset Management AS, Envestnet Asset Management Inc., Sanders Morris Harris LLC, Gradient Investments LLC, Fulton Bank N. A., and Patriot Financial Group Insurance Agency LLC. View insider buying and selling activity for BioMarin Pharmaceutical.

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BMRN stock can currently be purchased for approximately $126.06.

BioMarin Pharmaceutical has a market capitalization of $22.80 billion and generates $1.70 billion in revenue each year. The biotechnology company earns $-23,850,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. BioMarin Pharmaceutical employs 3,001 workers across the globe.

The official website for BioMarin Pharmaceutical is www.bmrn.com.

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]